Possible contamination of organ preservation fluid with Bacillus cereus: The United Kingdom response

Eurosurveillance

Volumn 17, Issue 18, 2012, Pages

  Brown, C S ^a   Chand, M A ^a,b   Hoffman, P ^a   Woodford, N ^a   Livermore, D M ^a   Brailsford, S ^a   Gharbia, S ^a   Small, N ^c   Billingham, E ^d   Zambon, M ^a   Grant, K ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^d NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRESERVATION SOLUTION;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACILLUS; BACILLUS CEREUS; BACILLUS CEREUS INFECTION; BACTERIUM CONTAMINATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD CULTURE; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; RISK ASSESSMENT; RISK MANAGEMENT; UNITED KINGDOM;

EID: 84862902495     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/ese.17.18.20165-en     Document Type: Article

References (21)

1. Southard JH, Belzer FO. Organ preservation. Annu Rev Med. 1995:46;235-247.
2. Medicines and Healthcare products Regulatory Agency (MHRA). Precautionary safety advice to transplant centres about Viaspan organ preservation solution manufactured by Bristol Myers Squibb Pharmaceuticals. London: MHRA. [Accessed 25 Apr 2012]. Available from: http://www.mhra.gov.uk/Safetyinformation/Healthcareproviders/Precautionarysafetyadvicetotransplantcentresabout-Viaspanorganpreservationsolutionmanufacturedby-BristolMyersSquibbPharmaceuticals/index.htm
3. European Commission (EC). Manufacture of sterile medicinal products (corrected version). Annex 1. In: EU guidelines to Good Manufacturing Practice. Medicinal products for human and veterinary use. Volume 4. Brussels; EC; 2008. Available from: http://ec.europa.eu/health/files/eudralex/vol-4/2008_11_25_gmp-an1_en.pdf
4. ®. Rueil-Malmaison: BMS. Press release. [Accessed 25 April 2012]. Available from: http://www.bms.com/news/features/2012/Pages/viaspan-03302012.aspx
5. Bristol-Myers Squibb (BMS). Bristol-Myers Squibb final quality risk assessment. Rueil-Malmaison: BMS; 11 April 2012.
6. Bottone EJ. Bacillus cereus, a volatile human pathogen. Clin Microbiol Rev. 2010;23(2):382-398.
7. Thuler LC, Velasco E, de Souza Martins CA, de Faria LM, da Fonseca NP, Dias LM, et al. An outbreak of Bacillus species in a cancer hospital. Infect Control Hosp Epidemiol. 1998:19(11):856-858.
8. van Der Zwet WC, Parlevliet GA, Savelkoul PH, Stoof J, Kaiser AM, van Furth AM, et al. Outbreak of Bacillus cereus infections in a neonatal intensive care unit traced to balloons used in manual ventilation. J Clin Microbiol. 2000;38(11):4131-4136.
9. Medicines and Healthcare products Regulatory Agency (MHRA), Health Protection Agency (HPA) and NHS Blood & Transplant (NHSBT). Possible contamination of Viaspan organ transport fluid. Information for clinicians. MHRA, HPA and NHSBT; 5 April 2012. Available from: http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con149657.pdf
10. Health Protection Agency (HPA). Major changes to reporting practices for laboratory communicable disease reporting. London: HPA. [Accessed 6 Apr 2012]. Available from: http://www.hpa.org.uk/ProductsServices/InfectiousDiseases/ServicesActivities/Surveillance/SourcesOfSurveillanceData/survGuidanceChanges/
11. Vilas-Bôs GT, Peruca AP, Arantes OM. Biology and taxonomy of Bacillus cereus, Bacillus anthracis, and Bacillus thuringiensis. Can J Microbiol. 2007;53:673-687
12. Andrews JM, Wise R. Susceptibility testing of Bacillus species. J Antimicrob Chemother. 2002;49(6):1040-1042.
13. Kiyomizu K, Yagi T, Yoshida H, Minami R, Tanimura A, Karasuno T, et al. Fulminant septicemia of Bacillus cereus resistant to carbapenem in a patient with biphenotypic acute leukemia. J Infect Chemother. 2008;14(5):361-367.
14. Katsuya H, Takata T, Ishikawa T, Sasaki H, Ishitsuka K, Takamatsu Y, et al. A patient with acute myeloid leukemia who developed fatal pneumonia caused by carbapenem-resistant Bacillus cereus. J Infect Chemother 2009;15(1):39-41.
15. Hussain M, Carlino A, Madonna MJ, Lampen JO. Cloning and sequencing of the metallothioprotein beta-lactamase II gene of Bacillus cereus 569/H in Escherichia coli. J Bacteriol. 1985;164(1):223-229.
16. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints. EUCAST. [Accessed 6 Apr 2012]. Available from: http://www.eucast.org/clinical_breakpoints/
17. Luna VA, King DS, Gulledge J, Cannons AC, Amuso PT, Cattani J. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods. J Antimicrob Chemother. 2007;60(3):555-567.
18. ® organ perfusion solution. Stockholm: ECDC; 23 April 2012. Rapid risk assessment. Available from: http://www.ecdc.europa.eu/en/publications/Publications/1204-TER-Risk-assessment-contaminationperfusion-solution.pdf
19. Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO). Guidance on the microbiological safety of human organs, tissues and cells used in transplantation. London: SaBTO; February 2011. Available from: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_130515.pdf
20. Austrian Medicines Authority. Rapid alert notification AT/ II/23/01. Vienna: Austrian Medicines Authority; 29 March 2012. Confidential report.
21. European Commission. Directive 2010/45/EU of the European Parliament and of the Council of 7 July 2010 on standards of quality and safety of human organs intended for transplantation. Luxembourg: Publications Office of the European Union. 6.8.2010:L 207/14. Available from: http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:207:0014:0029:EN:PDF